{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:23:31Z","timestamp":1790915011080,"version":"4.1.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002777","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T13:23:25Z","timestamp":1554470605000},"page":"e1002777","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":77,"title":["Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial"],"prefix":"10.1371","volume":"16","author":[{"given":"Norberto","family":"Perico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-0879","authenticated-orcid":true,"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9257-0283","authenticated-orcid":true,"given":"Annalisa","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4130-4663","authenticated-orcid":true,"given":"Anna","family":"Caroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-1729","authenticated-orcid":true,"given":"Matias","family":"Trillini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Sironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-8464","authenticated-orcid":true,"given":"Massimo","family":"Imbriaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5120-7883","authenticated-orcid":true,"given":"Mauro","family":"Dugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Morana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Figuera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5941-3481","authenticated-orcid":true,"given":"Flavio","family":"Gaspari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rubis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Prandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-7069","authenticated-orcid":true,"given":"Monica","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4301-8927","authenticated-orcid":true,"given":"Andrea","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6194-3446","authenticated-orcid":true,"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ALADIN 2 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","article-title":"Autosomal dominant polycystic kidney disease: the changing face of clinical management","volume":"385","author":"AC Ong","year":"2015","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/ki.2014.120","article-title":"Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease","volume":"86","author":"EM Spithoven","year":"2014","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"VE Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"FA Belibi","year":"2004","journal-title":"Kidney Int"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"JJ Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"ref6","first-page":"21","article-title":"Perspectives of new potential therapeutic applications of somatostatin analogs","volume":"24","author":"M Pawlikowski","year":"2003","journal-title":"Neuro Endocrinol Lett"},{"key":"ref7","first-page":"25","article-title":"Somatostatin inhibits CNP-induced stimulation of shark rectal gland","volume":"40","author":"P Silva","year":"1991","journal-title":"Bull Mt Desert Isl Biol Lab Salisb Cove Maine"},{"key":"ref8","first-page":"1323","article-title":"Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta","volume":"77","author":"JC Reubi","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","article-title":"Octreotide","volume":"334","author":"SW Lamberts","year":"1996","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"C Susini","year":"2006","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"P Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide","volume":"5","author":"A Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2019,5\u2019-cyclic monophosphate","volume":"132","author":"TV Masyuk","year":"2007","journal-title":"Gastroenterol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"A Caroli","year":"2013","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"D Ravine","year":"1994","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1681\/ASN.V62257","article-title":"Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate","volume":"6","author":"F Gaspari","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"N Perico","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.09900915","article-title":"Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4","volume":"11","author":"P Ruggenenti","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"e0178488","DOI":"10.1371\/journal.pone.0178488","article-title":"Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease","volume":"12","author":"K Sharma","year":"2017","journal-title":"PLoS ONE"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"AB Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cgh.2015.12.049","article-title":"Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease","volume":"14","author":"A Pisani","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","article-title":"Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates","volume":"48","author":"P Peduzzi","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"ref24","first-page":"1","article-title":"NParCov3: a SAS\/IML macro for nonparametric randomization-based analysis of covariance","volume":"50","author":"RC Zink","year":"2012","journal-title":"J Stat Softw"},{"key":"ref25","first-page":"5","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Summary of recommendation statements","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"MV Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0022-3476(87)80011-2","article-title":"Somatostatin limits rise in glomerular filtration rate after a protein meal","volume":"110","author":"BH Brouhard","year":"1987","journal-title":"J Pediatr"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1210\/jcem-64-5-975","article-title":"Renal response to intravenous somatostatin in insulin-dependent diabetic patients and normal subjects","volume":"64","author":"J Vora","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/0016-5085(92)91446-B","article-title":"Effects of somatostatin on renal function in cirrhosis","volume":"103","author":"A Gines","year":"1992","journal-title":"Gastroenterology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"A Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1681\/ASN.2012040390","article-title":"Mechanisms and treatment of CKD","volume":"23","author":"P Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1046\/j.1523-1755.2001.0600031131.x","article-title":"Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease","volume":"60","author":"TH Jafar","year":"2001","journal-title":"Kidney Int"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0272-6386(03)00193-8","article-title":"High urine volume and low urine osmolality are risk factors for faster progression of renal disease","volume":"41","author":"LA Hebert","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"O Devuyst","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ki.1989.38","article-title":"The clinical utility of renal concentrating capacity in polycystic kidney disease","volume":"35","author":"PA Gabow","year":"1989","journal-title":"Kidney Int"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"F931","DOI":"10.1152\/ajprenal.00604.2013","article-title":"The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors","volume":"306","author":"KV Juul","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"E Meijer","year":"2018","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40264-016-0486-x","article-title":"Hepatic cyst infection during use of the somatostatin analog lanreotide in autosomal dominant polycystic kidney disease: an interim analysis of the randomized open-label multicenter DIPAK-1 study","volume":"40","author":"MA Lantinga","year":"2017","journal-title":"Drug Saf"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"MC Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.2165\/00003495-200363220-00014","article-title":"Octreotide long-acting release (LAR): a review of its use in the management of acromegaly","volume":"63","author":"K McKeage","year":"2003","journal-title":"Drugs"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3748\/wjg.v21.i6.1945","article-title":"Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review","volume":"21","author":"MS Broder","year":"2015","journal-title":"World J Gastroenterol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1681\/ASN.V1181505","article-title":"2nd, Torres VE. Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease","volume":"11","author":"BF King","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"c195","DOI":"10.1159\/000327614","article-title":"Is doubling of serum creatinine a valid clinical \u2018hard\u2019 endpoint in clinical nephrology trials?","volume":"119","author":"HJ Lambers Heerspink","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"ref44","article-title":"Clinical trials: a practical approach","author":"SJ Pocock","year":"1983"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"e0190430","DOI":"10.1371\/journal.pone.0190430","article-title":"The prevalence of autosomal dominant polycystic kidney disease (ADPKD): a meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition","volume":"13","author":"A Solazzo","year":"2018","journal-title":"PLoS ONE"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijcard.2018.10.063","article-title":"Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: a cross-sectional and longitudinal substudy of the ALADIN trial","volume":"275","author":"L Spinelli","year":"2019","journal-title":"Int J Cardiol"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T06:36:13Z","timestamp":1663223773000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002777"}},"subtitle":[],"editor":[{"given":"Maarten W.","family":"Taal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002777","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]}}}